Cellulose Or Derivative Patents (Class 424/480)
-
Patent number: 7270831Abstract: Sustained release oral solid dosage forms of opioid analgesics are provided as multiparticulate systems which are bioavailable and which provide effective blood levels of the opioid analgesic for at least about 24 hours. A unit dose of the opioid analgesic contains a plurality of substrates including the opioid analgesic in sustained release form. The substrates have a diameter from about 0.1 mm to about 3 mm.Type: GrantFiled: March 20, 2003Date of Patent: September 18, 2007Inventors: Benjamin Oshlack, Mark Chasin
-
Publication number: 20070196491Abstract: A pharmaceutical dosage form such as a capsule, a conventional or orally disintegrating tablet capable of delivering a nitrogen (N)-containing therapeutic agent having a pKa in the range of from about 5 to 14 into the body in a sustained-released fashion, in order to be suitable for a twice- or once-daily dosing regimen, comprises at least one organic acid, which solubilizes the therapeutic agent the drug prior to releasing it into the hostile intestinal environment wherein said weakly basic drug is practically insoluble. The unit dosage form is composed of a multitude of multicoated particulates (i.e., immediate-release beads, sustained-release beads and/or one or more timed, pulsatile-release bead populations) is designed in such a way that said weakly basic drug and said organic acid do not come into close contact during processing and/or storage for in-situ formation of acid addition compounds while ensuring that the acid is not depleted prior to completion of the drug release.Type: ApplicationFiled: January 29, 2007Publication date: August 23, 2007Applicant: EURAND, INC.Inventor: Gopi M. Venkatesh
-
Patent number: 7235258Abstract: Sustained-release compositions for delivering therapeutic concentrations of isovaleramide, isovaleric acid, and certain structurally related compounds are provided for the treatment for a variety of pathological conditions, including epilepsy and spasticity, which are ameliorated by effecting a modulation of CNS activity. The ability of the compositions to sustain relatively constant levels of the drug at a therapeutic dose in the serum for extended periods of time enables a once or twice daily administration schedule.Type: GrantFiled: October 19, 2000Date of Patent: June 26, 2007Assignee: NPS Pharmaceuticals, Inc.Inventors: David S. Wells, Lian G. Rajewski, Thomas B. Marriott, James D. Pipkin, John L. Haslam
-
Patent number: 7235253Abstract: A method is disclosed for stabilizing a physiologically active peptide in a process of preparing a powder containing the physiologically active peptide by drying an aqueous liquid containing the physiologically active peptide, wherein the method comprises adding to the aqueous liquid at least one compound selected from the group consisting of a nonionic surfactant, a water-soluble, nonionic, organic binder, hydrogenated lecithin, and mannitol.Type: GrantFiled: November 28, 2001Date of Patent: June 26, 2007Assignee: JCR Pharmaceuticals Co., Ltd.Inventors: Yoshinobu Hanyu, Mariko Okada, Chihiro Shindo, Satoshi Nishimuro, Tetsuo Yokoyama, Masato Horie
-
Patent number: 7229643Abstract: The invention provides a pharmaceutically elegant solid oral formulation of olanzapine and a process for making such formulation.Type: GrantFiled: July 8, 2004Date of Patent: June 12, 2007Assignee: Eli Lilly and CompanyInventors: George Randall Cochran, Tommy Clifford Morris
-
Patent number: 7229642Abstract: Disclosed herein is a oral extended release dosage form comprising a plurality of granules of an effective amount of a pharmaceutically active compound, at least one amino acid, and an intragranular polymer in which the granule is dispersed within a hydrophilic extragranular polymer matrix which is more rapidly hydrating than the intragranular polymer. The amino acid is selected for hydropathy characteristics depending on solubility characteristics of the active compound.Type: GrantFiled: June 22, 2005Date of Patent: June 12, 2007Assignee: Scolr, Inc.Inventors: A. Reza Fassihi, Thomas Dürig
-
Patent number: 7214387Abstract: The invention provides sustained release formulations of metformin or a pharmaceutically acceptable salt thereof, and methods of treating diabetes by administering to a patient a therapeutically effective amount of a sustained release formulation of metformin or a pharmaceutically acceptable salt thereof.Type: GrantFiled: July 30, 2003Date of Patent: May 8, 2007Assignee: Penwest Pharmaceuticals CompanyInventors: Pradeep P. Sanghvi, Sara Ketsela
-
Patent number: 7195769Abstract: A pharmaceutical composition of anti-tubercular drugs for oral use comprising Rifampicin and/or Isoniazid wherein the bioavailability of Rifampicin and/or other drugs is enhanced. Preferably the bioavailability of Rifampicin is enhanced by preventing its degradation caused by presence of Isoniazid. Rifampicin and/or Isoniazid may be present in delayed release and/or extended release form such that minimal amount of the drug is dissolved between pH 1 and 4. preferably delayed release of Rifampicin and/or Isoniazid is achieved by treating the drugs with pH sensitive polymers.Type: GrantFiled: April 10, 2001Date of Patent: March 27, 2007Assignee: Panacea Biotec LimitedInventors: Amarjit Singh, Rajesh Jain
-
Patent number: 7163696Abstract: The invention provides a controlled-release pharmaceutical formulation for oral administration comprising 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or a pharmaceutically acceptable salt thereof; and a pharmaceutically acceptable adjuvant, diluent or carrier; characterized in that the formulation is adapted to release at least 50% by weight of the 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4-tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline, or the pharmaceutically acceptable salt thereof, after 6 hours in Apparatus 1 described in the United States Pharmacopoeia 24 (2000), pp 1941–1943, having 1 litre vessels, baskets of 40 mesh (0.4 mm apertures), a rotation speed of 100 rpm, and a dissolution medium consisting of 900 ml of 0.01 M hydrochloric acid containing 0.7% w/v sodium chloride at 37° C. Formulations according to the invention are suitable for the treatment of BPH.Type: GrantFiled: October 10, 2002Date of Patent: January 16, 2007Assignee: Pfizer Inc.Inventors: John Douglas Davis, Michael John Humphrey, Ross James Macrae, Janet Sarah Smith
-
Patent number: 7125567Abstract: Disclosed is an oral sustained-release preparation which contains at least one active ingredient selected from the group consisting of fasudil hydrochloride and a hydrate thereof, the preparation comprising at least one sustained-release coated particle comprising a core having a surface and a coating formed on the surface of the core, wherein the core contains the active ingredient and the coating comprises a coating base material and a specific insoluble auxiliary material, and wherein the preparation exhibits, with respect to the active ingredient, a specific dissolution rate, as measured by the dissolution test. By using the oral sustained-release preparation of the present invention, it becomes possible to surely control the release of fasudil hydrochloride from the preparation, so that the effect of the active ingredient is maintained for a long period of time.Type: GrantFiled: December 22, 2003Date of Patent: October 24, 2006Assignee: Asahi Kasei Pharma CorporationInventors: Tomokazu Sugi, Fumihide Nishio
-
Patent number: 7094426Abstract: The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such a dosage forms, and to a method of gastric acid pump inhibition and providing gastrointestinal cytoprotective benefit by using them.Type: GrantFiled: April 26, 2004Date of Patent: August 22, 2006Assignee: Sage Pharmaceuticals, Inc.Inventor: Jivn-Ren Chen
-
Patent number: 7081255Abstract: The present invention is concerned with novel pharmaceutical compositions of itraconazole which can be administered to a mammal suffering from a fungal infection, whereby a single such dosage form can be administered once daily, and in addition at any time of the day independently of the food taken in by said mammal. These novel compositions comprise particles obtainable by melt-extruding a mixture comprising itraconazole and an appropriate water-soluble polymer and subsequently milling said melt-extruded mixture.Type: GrantFiled: August 14, 2002Date of Patent: July 25, 2006Assignee: Janssen Pharmaceutica, N.V.Inventors: Lieven Elvire Colette Baert, Geert Verreck, Dany Thoné
-
Patent number: 7074430Abstract: A controlled release preparation for oral administration contains tramadol, or a pharmaceutically acceptable salt thereof, as active ingredient.Type: GrantFiled: March 6, 2001Date of Patent: July 11, 2006Assignee: Euro-Celtique S.A.Inventors: Ronald Brown Miller, Sandra Therese Antoinette Malkowska, Walter Wimmer, Udo Hahn, Stewart Thomas Leslie, Kevin John Smith, Horst Winkler, Derek Allan Prater
-
Patent number: 7063862Abstract: Embodiments of the invention generally provide pharmaceutical drug compositions, methods of preparing oral drug compositions, such as extended release dosage compositions, and methods for treating infection. More particularly, the invention relates to formulations containing a drug and a carrier material. In one aspect, the invention provides a pharmaceutical formulation including a therapeutically active agent, from about 0.1% to about 4.9% by weight of a pharmaceutically acceptable polymer, and from about 0.1% to about 30% by weight of a pharmaceutically acceptable acid, wherein the pharmaceutical composition have a zero order release profile of the therapeutically active agent. In another aspect, the invention provides methods for preparing and administering a pharmaceutical antibiotic composition in oral dosage form, such as a tablet.Type: GrantFiled: June 3, 2003Date of Patent: June 20, 2006Assignee: BioKey, Inc.Inventors: Jenny Li-Ying Lin, David Wong, San-Laung Chow
-
Patent number: 7041316Abstract: The present invention relates to new stable enteric coated pharmaceutical dosage forms for oral use containing Omeprazole or Lansoprazole, to a formulation and a method for the manufacture of such a dosage forms, and to a method of gastric acid pump inhibition and providing gastrointestinal cytoprotective benefit by using them.Type: GrantFiled: April 24, 2003Date of Patent: May 9, 2006Assignee: Sage Pharmaceuticals, Inc.Inventor: Jivn-Ren Chen
-
Patent number: 7037523Abstract: The present invention provides a controlled release pharmaceutical composition of an acid labile, poorly soluble drug having pH dependent solubility profile in aqueous environment. In a preferred embodiment the drug is combined with a practically water insoluble polymer an optimizing agent and optional additives to produce a controlled release of therapeutic agent when compositions is exposed to aqueous environment.Type: GrantFiled: November 1, 2002Date of Patent: May 2, 2006Assignee: Wockhardt LimitedInventors: Javed Hussain, Pankaj Khapra, Arun S. Gosavi
-
Patent number: 7022342Abstract: A sustained release beta-adrenergic receptor blocking agent, preferably propranolol, formulation.Type: GrantFiled: March 28, 2002Date of Patent: April 4, 2006Assignee: Andrx Corporation, Inc.Inventors: Chih-Ming Chen, Xiu Xiu Cheng
-
Patent number: 7022339Abstract: There is provided a single preparation which directly decreases both of the post prandial blood glucose level and the fasting blood glucose level close to normal levels, by release-sustaining a drug capable of decreasing the post prandial blood glucose level of diabetic patients close to the normal level, or mixing a controlled release drug capable of decreasing the post prandial blood glucose level close to the normal level with an immediate release drug. It is particularly preferable that the drug capable of decreasing the post prandial blood glucose level close to the normal level is nateglinide.Type: GrantFiled: June 28, 2002Date of Patent: April 4, 2006Assignee: Ajinomoto Co., Inc.Inventors: Chisato Makino, Nobutaka Ninomiya, Haruo Orita, Hidetoshi Sakai, Akira Yabuki, Nobuo Kato, Shigeru Shioya
-
Patent number: 7018630Abstract: A Bacillus natto culture is treated with chitosan, and then filtered, concentrated, and dried. According to this method, a Bacillus natto culture extract containing nattokinase and 1 ?g or less of vitamin K2/g dry weight is obtained.Type: GrantFiled: January 22, 2004Date of Patent: March 28, 2006Assignee: Japan Bio Science Laboratories, Inc.Inventor: Shinsaku Takaoka
-
Patent number: 7011848Abstract: An orally administered antihyperlipidemia composition according to the present invention includes from about 250 to about 3000 parts by weight of nicotinic acid, and from about 5 to about 50 parts by weight of hydroxypropyl methylcellulose. Also, a method of treating hyperlipidemia in a hyperlipidemic having a substantially periodic physiological loss of consciousness, includes the steps of forming a composition having an effective antihyperlipidemic amount of nicotinic acid and a time release sustaining amount of a swelling agent. The method also includes the step of orally administering the composition to the hyperlipidemic once per day “nocturnally,” that is in the evening or at night.Type: GrantFiled: December 22, 1999Date of Patent: March 14, 2006Assignee: KOS Pharmaceuticals, Inc.Inventor: David J. Bova
-
Patent number: 7011847Abstract: Pharmaceutical compositions and methods of using the composition are provided. The pharmaceutical composition comprises an inert core surrounded by an active coating containing one or more bisphosphonic acids or salts thereof, a seal coating surrounding the active coating and an enteric coating surrounding the seal coating. Alendronic acid and alendronate sodium trihydrate are the preferred active ingredients. The composition may be provided in the form of pellets in a capsule or Peltabs. The invention further provides methods for the treatment of disorders caused by the abnormal dissolution or deposition of calcium salts using the inventive compositions.Type: GrantFiled: October 16, 2003Date of Patent: March 14, 2006Assignee: U & I Pharmaceuticals Ltd.Inventors: Amar Lulla, Geena Malhotra
-
Patent number: 6994873Abstract: This invention refers to: multiparticulate formulations of Lithium salts for oral administration constituted by either modified release granules or mixtures of modified and conventional release granules, suitable for once-a-day administration also at high strengths of Lithium salts, and to the preparation process of said formulations.Type: GrantFiled: February 4, 2002Date of Patent: February 7, 2006Assignee: Valpharma S.A.Inventors: Roberto Valducci, Tiziano Alighieri, Serozh Avanessian
-
Patent number: 6989159Abstract: Once daily pharmaceutical compositions containing lithium carbonate in the form of coated granules.Type: GrantFiled: August 6, 2001Date of Patent: January 24, 2006Assignee: JDS Pharmaceuticals, LLCInventor: Giulio Tarro
-
Patent number: 6974591Abstract: The invention concerns a method for producing a controlled-release pharmaceutical preparation with a particle-containing coating, the coating being derived from an aqueous dispersion of a film-forming water insoluble polymer and a water soluble pore-forming agent. By suspending, instead of dissolving the pore-forming agent, the resulting coating will contain particles of the pore-formers with a predetermined size that creates, when disintegrated or dissolved in the body fluid, canals or a network of pores through the polymer film. Due to this network, the film will get a good mechanical stability and are left intact after the release of the drug.Type: GrantFiled: March 29, 2001Date of Patent: December 13, 2005Assignee: Watson Laboratories, Inc.Inventors: John Kendrup, Peter Fyhr
-
Patent number: 6964780Abstract: The invention provides controlled-release formulations for oral administration containing a cGMP PDE-5 inhibitor. The formulations are useful, inter alia, in the treatment or prevention of sexual dysfunction.Type: GrantFiled: October 22, 1999Date of Patent: November 15, 2005Assignee: Pfizer Inc.Inventors: Elizabeth King, Ross James Macrae
-
Patent number: 6960357Abstract: The invention provides a controlled release dissolution and diffusion devices which can deliver an active ingredient at a constant or controlled-variable rate comprising an active ingredient and dissolution modifiers and/or an insoluble matrix. The compressed core is coated, except for at least one exposed face, with a coating containing an insoluble polymer or a mixture of an insoluble polymer and pore-forming elements said pore-forming elements having a dissolution rate slower that the release rate so that the pore formation is completed after release of the active ingredients and the residual inert structures disintegrate.Type: GrantFiled: February 28, 2002Date of Patent: November 1, 2005Assignee: Mistral Pharma Inc.Inventor: Sham Chopra
-
Patent number: 6958161Abstract: A modified release preparation having one or more coated core elements, each core element including an active ingredient and having a modified release coating, wherein a stabilising coat is provided between each core element and its modified release coating so that, upon in vitro dissolution testing, the amount of active ingredient released at any time on a post-storage dissolution profile is within 40 percentage points of the amount of active ingredient released at any time on a pre-storage dissolution profile.Type: GrantFiled: April 12, 2002Date of Patent: October 25, 2005Assignee: F H Faulding & Co LimitedInventors: David Hayes, Angelo LoPore, Stefan Lukas, Eugene Quinn
-
Patent number: 6946146Abstract: The present invention is directed to a coating composition for coating a solid dosage form of a medicament, where the coating composition controls the release of the medicament, said coating composition comprising (a) at least 50% (w/w) by dry weight of a water insoluble polymer insoluble in both acidic, basic and neutral pH, present in the form of an aqueous latex dispersion, (b) a water soluble non-polymeric component present in a weight ratio of about 5 to about 50% (w/w) by dry weight of the coating, having a molecular weight of less than about 15,000 daltons and water solubility in excess of 5 grams per 100 grams of water at room temperature at 1 atm pressure, said water soluble non-polymeric component being organic and either solid or liquid; said ratio of water insoluble polymer to water soluble non-polymeric component ranging from about 95:5 to about 1:1, the solid content in the coating composition ranges from about 5% to about 25%, said water soluble component being completely dissolved in the aqueoType: GrantFiled: April 18, 2002Date of Patent: September 20, 2005Assignee: Nostrum Pharmaceuticals Inc.Inventor: Nirmal Mulye
-
Patent number: 6939560Abstract: The present invention provides a pharmaceutical composition which is substantially free of unpleasant tastes and orally administrable which comprises: (a) an active medicament, (b) an inner coating layer comprising an oil substance having a melting point at a range of from about 50° C. to about 100° C., (c) an outer coating layer comprising at least a polymeric substance.Type: GrantFiled: December 15, 2000Date of Patent: September 6, 2005Assignee: Pharmacia & Upjohn CompanyInventors: Robert W. Shen, Gerald A. Walter
-
Patent number: 6926907Abstract: The present invention is directed to drug dosage forms that release an agent that raises the pH of a patient's gastrointestinal tract, followed by a non-steroidal anti-inflammatory drug. The dosage form is designed so that the NSAID is not released until the intragastric pH has been raised to a safe level. The invention also encompasses methods of treating patients by administering this coordinated release, gastroprotective, antiarthritic/analgesic combination unit dosage form to achieve pain and symptom relief with a reduced risk of developing gastrointestinal damage such as ulcers, erosions and hemorrhages.Type: GrantFiled: May 31, 2002Date of Patent: August 9, 2005Assignee: Pozen Inc.Inventor: John R. Plachetka
-
Patent number: 6902609Abstract: The present invention is directed to film coating systems for use on oral dosage forms such as compressed tablets and orally-ingestible substrates which have improved pearlescent qualities. The film coating systems can be applied either directly to a substrate or after the substrate has been coated with a subcoat. In preferred aspects, the pearlescent film coating is prepared as a dry powder mixture containing a cellulosic polymer, a detackifier, a gloss enhancer, and a pearlescent pigment. Film coating compositions containing an aqueous suspension of the powder mixtures, methods of applying the coatings to substrates and the coated substrates are also disclosed.Type: GrantFiled: February 13, 2004Date of Patent: June 7, 2005Assignee: BPSI Holdings, Inc.Inventors: Rita M. Steffenino, Franklin J. Gulian, Irvin M. Lash, Thomas P. Farrell, Charles D. Fields
-
Patent number: 6899896Abstract: A controlled release dosage form for sertraline has a core comprising a sertraline-containing composition and a water-swellable composition wherein the water-swellable composition is in a separate region within the core. A coating around the core is water-permeable, water-insoluble, and has at least one delivery port therethrough. In one embodiment, the dosage form releases sertraline to the use environment at an average rate of 6 to 10 wt % per hour from the second to the twenth hour after introduction to a use environment and less than about 25 wt % for the first two hours and at least 70 wt % by the twelfth hour, where the percentages correspond to the mass of drug released from the tablet divided by the total mass of drug originally present in the tablet.Type: GrantFiled: December 20, 2000Date of Patent: May 31, 2005Assignee: Pfizer IncInventors: William J. Curatolo, Kenneth C. Waterman, Avinash G. Thombre, Michael B. Fergione, Michael C. Roy, Leah A. Appel, Danni Supplee, Dwayne T. Friesen, Mark B. Chidlaw, Ronald A. Beyerinck
-
Patent number: 6893662Abstract: The present invention relates to a pharmaceutical composition in a solid unit dosage form for oral administration in a human or lower animal comprising: a. a safe and effective amount of a therapeutically active agent; b. an inner coating layer selected from the group consisting of poly(methacrylic acid, methyl methacrylate) 1:2, poly(methacrylic acid, methyl methacrylate) 1:1, and mixtures thereof; and c. an outer coating layer comprising an enteric polymer or film coating material; wherein the inner coating layer is not the same as the outer coating layer; wherein if the inner coating layer is poly(methacrylic acid, methyl methacrylate) 1:1 then the outer coating layer is not poly(methacrylic acid, methyl methacrylate) 1:2 or is not a mixture of poly(methacrylic acid, methyl methacrylate) 1:1 and poly(methacrylic acid, methyl methacrylate) 1:2; and wherein the inner coating layer and the outer coating layer do not contain any therapeutically active agent.Type: GrantFiled: November 15, 2001Date of Patent: May 17, 2005Assignee: The Procter & Gamble CompanyInventors: Gregory Paul Dittmar, Joseph Michael Amante, Tony Ryan Cronk, Daniel Gary Newby
-
Patent number: 6890550Abstract: Method of preventing parturient hypocalcemia and milk fever (parturient paresis) in lactating animals comprising administering to the animal during the dry period a compound which reduces absorption of calcium from the drinking water and/or from the ration of said animal. The method is based on the powerful, natural calcium regulating mechanisms and is applicable under commercial farming conditions.Type: GrantFiled: March 17, 2000Date of Patent: May 10, 2005Assignee: RJ InnovationInventor: Rolf Jess Jorgensen
-
Patent number: 6884288Abstract: An edible dry-powder formulation of a film coating for pharmaceuticals and confectioneries using gum acacia as a low-cost film former is provided. A cellulosic polymer such as hydroxypropyl methylcellulose is used in addition to the gum acacia. A plasticizer such as propylene glycol is also added. The resulting formulation is a dry, free flowing powder that can be put into solution and applied to a tablet or other substrate without an extended waiting period. The resulting film coating is clear, shiny, durable and extremely economical. Because the formulation is a dry powder, it has along shelf life and low shipping costs.Type: GrantFiled: November 12, 2003Date of Patent: April 26, 2005Assignee: Chr. Hansen, Inc.Inventors: Charles W. Gayser, Jr., Jean-Paul Goyette
-
Patent number: 6872407Abstract: Disclosed is a pharmaceutical composition for extended release of an erythromycin derivative in the gastrointestinal environment. The composition comprises an erythromycin derivative and a pharmaceutically acceptable polymer so that, when ingested orally, the composition induces statistically significantly lower Cmax in the plasma than an immediate release composition of the erythromycin derivative while maintaining bioavailability and minimum concentration substantially equivalent to that of the immediate release composition of the erythromycin derivative upon multiple dosing. The compositions of the invention have an improved taste profile and reduced gastrointestinal side effects as compared to those for the immediate release composition.Type: GrantFiled: November 22, 2002Date of Patent: March 29, 2005Assignee: Abbott LaboratoriesInventors: Gerard F. Notario, Robert N. Palmer, Richard C. Hom, Jie Zhang, Karen J. Devcich, Susan J. Semla
-
Patent number: 6866866Abstract: A composition for treating patients having non-insulin-dependent diabetes mellitus (NIDDM) by administering a controlled release oral solid dosage form containing preferably a biguanide drug such as metformin, on a once-a-day basis. The dosage form provides a mean time to maximum plasma concentration (Tmax) of the drug which occurs at 5.5 to 7.5 hours after oral administration on a once-a-day basis to human patients. Preferably, the dose of drug is administered at dinnertime to a patient in the fed state.Type: GrantFiled: November 3, 2000Date of Patent: March 15, 2005Assignee: Andrx Labs, LLCInventors: Chih-Ming Chen, Xiu-Xiu Cheng, Steve Jan, Joseph Chou
-
Patent number: 6852335Abstract: A nutritional tablet or caplet has a film coating that contains folic acid available for rapid release upon contact with gastric fluid. The film coating also includes a film forming polymer such as hydroxypropyl methylcellulose.Type: GrantFiled: June 5, 2002Date of Patent: February 8, 2005Assignee: Shaklee CorporationInventor: Douglas P. DeBernardi
-
Patent number: 6838094Abstract: A tablet formulation which comprises a core containing a pharmaceutically active material, coated with a release retarding coating, surrounded by a casing layer which includes a second pharmaceutically active material.Type: GrantFiled: December 18, 2001Date of Patent: January 4, 2005Assignee: SmithKline Beecham p.l.c.Inventors: Francis Walter Grimmett, Nigel Philip McCreath Davidson
-
Patent number: 6814979Abstract: Disclosed is an osmotic pharmaceutical delivery system comprising (a) a semi-permeable wall that maintains its integrity during pharmaceutical delivery and which has at least one passage therethrough; (b) a single, homogeneous composition within said wall, which composition consists essentially of (i) a pharmaceutically active agent, (ii) at least one non-swelling solubilizing agent which enhances the solubility of the pharmaceutically active agent; (iii) at least one non-swelling osmotic agent and (iv) a non-swelling wicking agent dispersed throughout the composition which enhances the surface area contact of the pharmaceutical agent with the incoming aqueous fluid.Type: GrantFiled: December 20, 2002Date of Patent: November 9, 2004Assignee: Shire Laboratories, Inc.Inventors: Edward M. Rudnic, Beth A. Burnside, Henry H. Flanner, Sandra E. Wassink, Richard A. Couch, Jill E. Pinkett
-
Patent number: 6808721Abstract: A formulation comprising, and process for preparing, improved oral dosage forms of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea, a chemical entity with anti-inflammatory properties. Granulation of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea within specified ranges provides improved dissolution of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea and oral bioavailability, as well as content uniformity. Incorporation into the formulation of an aqueous soluble inclusion compound capable of forming a complex with 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea, such as beta-cyclodextrin provides enhanced stability of 1-(5-tert-butyl-2-p-tolyl-2H-pyrazol-3-yl)-3-[4-(2-morpholin-4-yl-ethoxy)-naphthalen-1-yl]-urea, in particular in highly ionic environments.Type: GrantFiled: October 29, 2002Date of Patent: October 26, 2004Assignee: Boehringer Ingelheim Pharmaceuticals, Inc.Inventors: Michael Cappola, George W. Gereg, Susan Way
-
Patent number: 6794367Abstract: The invention provides solid preparations for oral administration of gene-related drugs comprising a core containing the gene-related drug with a coating which does not disintegrated in small intestines, wherein said preparations can be easily tabletted, remain stable during the preparation process and said drug can be efficiently absorbed in digestive tracts.Type: GrantFiled: November 20, 2000Date of Patent: September 21, 2004Assignee: Hisamitsu Pharmaceutical, Inc.Inventors: Norifumi Tanida, Takeshi Goto, Jun Aoki
-
Patent number: 6787156Abstract: A composition for controlled delivery of at least one active substance into an aqueous medium by erosion at a preprogrammed rate of at least one surface of the composition, comprising the active substance, the matrix being erodible in the aqueous medium in which the composition is to be used, and a coating having at least one opening exposing at least one surface of said matrix, the coating comprising a first cellulose derivative which has thermoplastic properties and which is substantially insoluble in the aqueous medium in which the composition is to be used, and at least one of a second cellulose derivative which is soluble or dispersible in water, a plasticizer, and a filler. The coating is a coating which crumbles and/or erodes upon exposure to the aqueous medium such as a body fluid. The first cellulose derivative may be, e.g., ethycellulose, cellulose acetate, cellulose propionate or cellulose nitrate, and the second cellulose derivative may be, e.g.Type: GrantFiled: August 19, 1996Date of Patent: September 7, 2004Assignee: BM Research A/SInventor: Daniel Bar-Shalom
-
Patent number: 6780436Abstract: The pharmaceutical formulation consists of a number of pellets that comprise an inert nucleus, a layer with the active ingredient, one or more intermediate layers that comprise at least a system of modified release, and an external layer of enteric coating. These pellets can be obtained applying the different layers by means of fluid bed coating techniques using aqueous solutions or suspensions of the components of such layers. The pharmaceutical formulations can be hard gelatin capsules or tablets and are suitable for use in the prevention and treatment of disorders related to abnormal gastric acid secretion.Type: GrantFiled: September 12, 2000Date of Patent: August 24, 2004Assignee: Laboratorios Del Dr. Esteve, SAInventors: Antonio López-Cabrera, Pedro Juan Solanas-Ibarra, Vincent Mancinelli
-
Patent number: 6780433Abstract: The invention provides a pharmaceutically elegant solid oral formulation of olanzapine and a process for making such formulation.Type: GrantFiled: January 19, 2001Date of Patent: August 24, 2004Assignee: Eli Lilly and CompanyInventors: George Randall Cochran, Tommy Clifford Morris
-
Patent number: 6761901Abstract: This invention comprises pharmaceutical compositions for administering a biologically active compound to an animal. Particularly provided are proliposomal compositions that are advantageously used to deliver biologically active compounds to the gastrointestinal tract after oral administration.Type: GrantFiled: May 2, 2000Date of Patent: July 13, 2004Assignee: EnzRel Inc.Inventors: Guru V. Betageri, Milton B. Yatvin
-
Publication number: 20040129174Abstract: A composition comprising a high molecular weight, water soluble polymer having a cloud point from about 20 to about 90° C. and at least one carrageenan is provided. The composition may be used as a component of a pharmaceutical dosage form, such as the shell of a dosage form, to provide burst release of active ingredient contained therein.Type: ApplicationFiled: October 28, 2003Publication date: July 8, 2004Inventors: Shun-Por Li, Der-Yang Lee, Frank J. Bunick, Jen Chi Chen, Harry S. Sowden
-
Patent number: 6753008Abstract: Compositions comprising a plurality of yeast cells, wherein said plurality of yeast cells are characterized by their ability to normalize the serum level of GPT, AP and/or LDH-5 in a mammal, said ability resulting from their having been cultured in the presence of an alternating electric field having a specific frequency and a specific field strength. Also included are methods of making and using these compositions.Type: GrantFiled: June 28, 2002Date of Patent: June 22, 2004Assignee: Ultra Biotech LimitedInventor: Ling Yuk Cheung
-
Patent number: RE39149Abstract: An oral dosage form of azithromycin which does not exhibit an adverse food effect; Specific azithromycin oral dosage forms including tablets, powders for oral suspensions and unit dose packets; Methods of treating microbial infections with the dosage forms; And therapeutic packages containing the dosage forms.Type: GrantFiled: January 20, 2005Date of Patent: June 27, 2006Assignee: Pfizer Inc.Inventors: William J. Curatolo, George H. Foulds, Hylar L. Friedman
-
Patent number: RE39239Abstract: The present invention provides methods of treating early morning pathologies using a time-specific controlled release dosage formulation which is administered prior to sleep, and which permits or achieves delivery of a pharmaceutically active agent effective for the treatment of the specific early morning pathology to be treated, at about the time of awakening. The time-specific controlled release dosage formulation comprises (1) a core including the pharmaceutically active agent(s) effective for the treatment of the early morning pathology, and (2) a swellable polymeric coating layer substantially surrounding the core. The swellable polymeric coating layer delays the release of the pharmaceutically active agent from the core for a predetermined period of time dependent upon the thickness of the swellable polymeric coating layer, to effect delivery of the pharmaceutically active agent at about the time of awakening.Type: GrantFiled: September 17, 2002Date of Patent: August 15, 2006Assignee: Polichem SAInventors: Cesare Busetti, Tiziano Crimella